Literature DB >> 33567746

SARS-CoV-2: An Update on Genomics, Risk Assessment, Potential Therapeutics and Vaccine Development.

Iqra Mehmood1, Munazza Ijaz1, Sajjad Ahmad2, Temoor Ahmed3, Amna Bari4, Asma Abro5, Khaled S Allemailem6, Ahmad Almatroudi6, Muhammad Tahir Ul Qamar7.   

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a great threat to public health, being a causative pathogen of a deadly coronavirus disease (COVID-19). It has spread to more than 200 countries and infected millions of individuals globally. Although SARS-CoV-2 has structural/genomic similarities with the previously reported SARS-CoV and MERS-CoV, the specific mutations in its genome make it a novel virus. Available therapeutic strategies failed to control this virus. Despite strict standard operating procedures (SOPs), SARS-CoV-2 has spread globally and it is mutating gradually as well. Diligent efforts, special care, and awareness are needed to reduce transmission among susceptible masses particularly elder people, children, and health care workers. In this review, we highlighted the basic genome organization and structure of SARS-CoV-2. Its transmission dynamics, symptoms, and associated risk factors are discussed. This review also presents the latest mutations identified in its genome, the potential therapeutic options being used, and a brief explanation of vaccine development efforts against COVID-19. The effort will not only help readers to understand the deadly SARS-CoV-2 virus but also provide updated information to researchers for their research work.

Entities:  

Keywords:  COVID-19 vaccines; SARS-CoV-2; genomic characterization; pandemic; pathophysiology; therapeutic strategies

Mesh:

Substances:

Year:  2021        PMID: 33567746     DOI: 10.3390/ijerph18041626

Source DB:  PubMed          Journal:  Int J Environ Res Public Health        ISSN: 1660-4601            Impact factor:   3.390


  12 in total

1.  Computational Investigations of Traditional Chinese Medicinal Compounds against the Omicron Variant of SARS-CoV-2 to Rescue the Host Immune System.

Authors:  Ziad Tareq Naman; Salim Kadhim; Zahraa J K Al-Isawi; Christopher J Butch; Ziyad Tariq Muhseen
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-13

2.  Molecular adaptive evolution of SARS-COV-2 spike protein in Saudi Arabia.

Authors:  Islam Nour; Ibrahim O Alenazi; Atif Hanif; Saleh Eifan
Journal:  Saudi J Biol Sci       Date:  2021-03-02       Impact factor: 4.219

3.  Rescuing the Host Immune System by Targeting the Immune Evasion Complex ORF8-IRF3 in SARS-CoV-2 Infection with Natural Products Using Molecular Modeling Approaches.

Authors:  Aqel Albutti
Journal:  Int J Environ Res Public Health       Date:  2021-12-23       Impact factor: 3.390

4.  Targeting the RBD of Omicron Variant (B.1.1.529) with Medicinal Phytocompounds to Abrogate the Binding of Spike Glycoprotein with the hACE2 Using Computational Molecular Search and Simulation Approach.

Authors:  Abdulrahim R Hakami
Journal:  Biology (Basel)       Date:  2022-02-07

Review 5.  Allergic Diseases: A Comprehensive Review on Risk Factors, Immunological Mechanisms, Link with COVID-19, Potential Treatments, and Role of Allergen Bioinformatics.

Authors:  Fahad M Aldakheel
Journal:  Int J Environ Res Public Health       Date:  2021-11-18       Impact factor: 3.390

6.  COVID-19-Vaccination-Induced Myocarditis in Teenagers: Case Series with Further Follow-Up.

Authors:  Mateusz Puchalski; Halszka Kamińska; Marta Bartoszek; Michał Brzewski; Bożena Werner
Journal:  Int J Environ Res Public Health       Date:  2022-03-15       Impact factor: 3.390

Review 7.  Therapeutic Strategies for COVID-19 Lung Disease in Children.

Authors:  Elisabetta Gatti; Marta Piotto; Mara Lelii; Mariacarola Pensabene; Barbara Madini; Lucia Cerrato; Vittoria Hassan; Stefano Aliberti; Samantha Bosis; Paola Marchisio; Maria Francesca Patria
Journal:  Front Pediatr       Date:  2022-03-07       Impact factor: 3.418

8.  Insights into the Binding of Receptor-Binding Domain (RBD) of SARS-CoV-2 Wild Type and B.1.620 Variant with hACE2 Using Molecular Docking and Simulation Approaches.

Authors:  Ziyad Tariq Muhseen; Salim Kadhim; Yahiya Ibrahim Yahiya; Eid A Alatawi; Faris F Aba Alkhayl; Ahmad Almatroudi
Journal:  Biology (Basel)       Date:  2021-12-10

9.  Case Report: Discovery a Novel SARS-CoV-2 Variant in a Six-Months Long-Term Swab Positive Female Suffering From Non-Hodgkin Lymphoma.

Authors:  Ettore Capoluongo; Carmela Nardelli; Maria Valeria Esposito; Antonio Riccardo Buonomo; Monica Gelzo; Biagio Pinchera; Emanuela Zappulo; Giulio Viceconte; Giuseppe Portella; Mario Setaro; Ivan Gentile; Giuseppe Castaldo
Journal:  Front Oncol       Date:  2021-07-20       Impact factor: 6.244

Review 10.  SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants.

Authors:  Daniel Martínez-Flores; Jesús Zepeda-Cervantes; Adolfo Cruz-Reséndiz; Sergio Aguirre-Sampieri; Alicia Sampieri; Luis Vaca
Journal:  Front Immunol       Date:  2021-07-12       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.